Expanded Access Multicenter Study of Lucanix® (Belagenpumatucel-L)

Non-small Cell Lung Cancer Clinical Trial

Official title:

Expanded Access Multicenter Study of Lucanix® (Belagenpumatucel-L) in Advanced Non-small Cell Lung Cancer.

Clinical Trial Details — Status: No longer available

Administrative data

• NCT number: NCT01279798
• Other study ID #: NR001-04
• Status: No longer available
• Phase: N/A
• First received: October 29, 2010
• Last updated: February 25, 2011

Study information

• Verified date: January 2011
• Source: NovaRx Corporation
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Expanded Access

Clinical Trial Summary

This is an expanded access protocol designed to make Lucanix® available to subjects with advanced non-small cell lung cancer (NSCLC) who are not eligible for the Phase III Protocol, NR001-03. A total of 45 patients will be enrolled into the study.

Description:

The primary objective of this study is to increase the overall survival of the study subjects by providing expanded access to Lucanix. Overall survival and progression-free survivals will be compared with historical controls.

The secondary objectives of this study are:

• Evaluate the best overall tumor response.

• Evaluate progression-free survival (PFS).

• Evaluate treatment toxicity.

Recruitment information / eligibility

• Status: No longer available
• Enrollment: 0
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Signed informed consent

• = 18 years

• Histological confirmed non-curable stage III or IV NSCLC.

• Must have completed at least one (1) regimen of anti-cancer therapy.

• Following frontline therapy, subjects must observe the following wash- out periods:

• Subjects with stable disease or better must have received the last anti-cancer therapy not less than five months prior to enrollment.

• Subjects with progressive disease must have received the last anti-cancer therapy at least one (1) month prior to enrollment.

• All subjects who have received two (2) or more regimens of therapy must have received the last anti-cancer therapy at least one (1) month prior to enrollment.

• Performance status (ECOG) = 2

• Absolute granulocyte count = 1,500/mm3

• Platelet count = 100,000/mm3

• Total Bilirubin = 2× Upper Limit of Normal

• AST and ALT = 2× Upper Limit of Normal

• Creatinine = 2× Upper Limit of Normal

• Negative pregnancy test for women of childbearing potential.

Exclusion Criteria:

• Concurrent systemic steroids > 2 mg prednisone/day

• Prior splenectomy

• Any chemotherapy, steroid therapy, or investigational anti-cancer agent within 4 weeks of study entry.

• Subjects who received prior monotherapy with Lucanix.

• Symptomatic brain metastases unless treated and stable for = 2 months

• Known HIV positivity

• Serious non-malignant disease (e.g., congestive heart failure, or active uncontrolled bacterial, viral, or fungal infections), or other conditions which, in the opinion of the investigator would compromise protocol objectives.

• Prior malignancy (excluding non-melanoma carcinomas of the skin) unless in remission for = 2 years

• History of psychiatric disorder that would impede adherence to protocol

• Pregnant or nursing women or refusal to practice contraception if of reproductive potential

Study Design

N/A

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non-small Cell Lung Cancer

Intervention

Biological:
• Lucanix® (belagenpumatucel-L)
Subjects will receive up to 12 monthly (28-35 day interval) Lucanix injections at a dose of 2.5 × 10e7 cells per injection.

Locations

Country	Name	City	State
United States	Innovative Research Center of California	San Diego	California

Sponsors (1)

Lead Sponsor	Collaborator
NovaRx Corporation

Country where clinical trial is conducted

United States, 

References & Publications (1)

Nemunaitis J, Dillman RO, Schwarzenberger PO, Senzer N, Cunningham C, Cutler J, Tong A, Kumar P, Pappen B, Hamilton C, DeVol E, Maples PB, Liu L, Chamberlin T, Shawler DL, Fakhrai H. Phase II study of belagenpumatucel-L, a transforming growth factor beta- — View Citation

External Links

•   NovaRx Website